Rasagiline tartrate is used experimentally for the treatment of Parkinson’s disease. It works by inhibiting MAO-B, helping to increase dopamine levels in the brain. This improves motor symptoms like tremors, stiffness, and slow movement. It is a research form, while rasagiline mesylate is the clinically approved version. It is grouped under the following drug class(es): Dopamine agents. Its therapeutic use is listed as central nervous system (CNS) agents. The directory classifies it as a unknown/inactive API with a synthetic source/manufacturing origin. Other names for this substance include Rasagiline hemitartrate, Rasagiline (TN) and UNII-B9A329CN07. Its PubChem CID is 71550735.
Rasagiline tartrate
| CAS No | 136236-52-7 |
|---|---|
| Molecular Formula | C28H32N2O6 |
| Molecular Weight | 492.6 g/mol |
| Synonyms | (2R,3R)-2,3-dihydroxybutanedioic acid;(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Rasagiline tartrate is used experimentally for the treatment of Parkinson’s disease. It works by inhibiting MAO-B, helping to increase dopamine levels in the brain.
The listed CAS number is 136236-52-7.
The listed molecular formula is C28H32N2O6.
The listed molecular weight is 492.6 g/mol.
(2R,3R)-2,3-dihydroxybutanedioic acid;(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine.
The source lists Rasagiline hemitartrate, Rasagiline (TN) and UNII-B9A329CN07.